Authors:
Kim, D
Wang, LP
Caldwell, CG
Chen, P
Finke, PE
Oates, B
MacCoss, M
Mills, SG
Malkowitz, L
Gould, SL
DeMartino, JA
Springer, MS
Hazuda, D
Miller, M
Kessler, J
Danzeisen, R
Carver, G
Carella, A
Holmes, K
Lineberger, J
Schleif, WA
Emini, EA
Citation: D. Kim et al., Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3099-3102
Authors:
Kim, D
Wang, LP
Caldwell, CG
Chen, P
Finke, PE
Oates, B
MacCoss, M
Mills, SG
Malkowitz, L
Gould, SL
DeMartino, JA
Springer, MS
Hazuda, D
Miller, M
Kessler, J
Danzeisen, R
Carver, G
Carella, A
Holmes, K
Lineberger, J
Schleif, WA
Emini, EA
Citation: D. Kim et al., Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3103-3106
Authors:
Hagmann, WK
Durette, PL
Lanza, T
Kevin, NJ
de Laszlo, SE
Kopka, HE
Young, D
Magriotis, PA
Li, B
Lin, LS
Yang, G
Kamenecka, T
Chang, LL
Wilson, J
MacCoss, M
Mills, SG
Van Riper, G
McCauley, E
Egger, LA
Kidambi, U
Lyons, K
Vincent, S
Stearns, R
Colletti, A
Teffera, J
Tong, S
Fenyk-Melody, J
Owens, K
Levorse, D
Kim, P
Schmidt, JA
Mumford, RA
Citation: Wk. Hagmann et al., The discovery of sulfonylated dipeptides as potent VLA-4 antagonists, BIOORG MED, 11(20), 2001, pp. 2709-2713
Authors:
Hale, JJ
Budhu, RJ
Holson, EB
Finke, PE
Oates, B
Mills, SG
MacCoss, M
Gould, SL
DeMartino, JA
Springer, MS
Siciliano, S
Malkowitz, L
Schleif, WA
Hazuda, D
Miller, M
Kessler, J
Danzeisen, R
Holmes, K
Lineberger, J
Carella, A
Carver, G
Emini, E
Citation: Jj. Hale et al., 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity, BIOORG MED, 11(20), 2001, pp. 2741-2745
Authors:
Dorn, CP
Finke, PE
Oates, B
Budhu, RJ
Mills, SG
MacCoss, M
Malkowitz, L
Springer, MS
Daugherty, BL
Gould, SL
DeMartino, JA
Siciliano, SJ
Carella, A
Carver, G
Holmes, K
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Schleif, WA
Emini, EA
Citation: Cp. Dorn et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 259-264
Authors:
Finke, PE
Meurer, LC
Oates, B
Mills, SG
MacCoss, M
Malkowitz, L
Springer, MS
Daugherty, BL
Gould, SL
DeMartino, JA
Siciliano, SJ
Carella, A
Carver, G
Holmes, K
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Schleif, WA
Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 265-270
Authors:
Finke, PE
Meurer, LC
Oates, B
Shah, SK
Loebach, JL
Mills, SG
MacCoss, M
Castonguay, L
Malkowitz, L
Springer, MS
Gould, SL
DeMartino, JA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: A proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)4-[4-(substituted)piperidin-1yl]butanes, BIOORG MED, 11(18), 2001, pp. 2469-2473
Authors:
Finke, PE
Oates, B
Mills, SG
MacCoss, M
Malkowitz, L
Springer, MS
Gould, SL
DeMartino, JA
Carella, A
Carver, G
Holmes, K
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Schleif, WA
Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes, BIOORG MED, 11(18), 2001, pp. 2475-2479
Authors:
Hale, JJ
Budhu, RJ
Mills, SG
MacCoss, M
Malkowitz, L
Siciliano, S
Gould, SL
DeMartino, JA
Springer, MS
Citation: Jj. Hale et al., 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: Discovery of the pyrrolidine scaffold and determination of its stereochemical requirements, BIOORG MED, 11(11), 2001, pp. 1437-1440
Authors:
Tattersall, FD
Rycroft, W
Cumberbatch, M
Mason, G
Tye, S
Williamson, DJ
Hale, JJ
Mills, SG
Finke, PE
MacCoss, M
Sadowski, S
Ber, E
Cascieri, M
Hill, RG
MacIntyre, DE
Hargreaves, RJ
Citation: Fd. Tattersall et al., The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L758,298, inhibit acute and delayed cisplatin-inducedemesis in ferrets, NEUROPHARM, 39(4), 2000, pp. 652-663
Authors:
Hale, JJ
Mills, SG
MacCoss, M
Dorn, CP
Finke, PE
Budhu, RJ
Reamer, RA
Huskey, SEW
Luffer-Atlas, D
Dean, BJ
McGowan, EM
Feeney, WP
Chiu, SHL
Cascieri, MA
Chicchi, GG
Kurtz, MM
Sadowski, S
Ber, E
Tattersall, FD
Rupniak, NMJ
Williams, AR
Rycroft, W
Hargreaves, R
Metzger, JM
MacIntyre, DE
Citation: Jj. Hale et al., Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs, J MED CHEM, 43(6), 2000, pp. 1234-1241